Gain Therapeutics Stock Analysis

Gain Stock Analysis Notes

The company recorded a loss per share of 1.07. Gain Therapeutics had not issued any dividends in recent years. Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. The company was founded in 2017 and is based in Bethesda, Maryland. Gain Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. To learn more about Gain Therapeutics call LLM IUR at 301 500 1556 or check out https://www.gaintherapeutics.com.

Gain Therapeutics Investment Alerts

Gain Therapeutics Upcoming and Recent Events

Gain Largest EPS Surprises

View All Earnings Estimates

Gain Therapeutics Environmental, Social, and Governance (ESG) Scores

Gain Stock Institutional Investors

Note, although Gain Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Gain Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.07 M.

Gain Profitablity

Management Efficiency

Gain Therapeutics has return on total asset (ROA) of (0.9413) % which means that it has lost $0.9413 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6314) %, meaning that it created substantial loss on money invested by shareholders. Gain Therapeutics' management efficiency ratios could be used to measure how well Gain Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.14 in 2025. Return On Capital Employed is likely to rise to -1.78 in 2025. At this time, Gain Therapeutics' Other Current Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.3 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 12.8 M in 2025.

Technical Drivers

As of the 23rd of March, Gain Therapeutics retains the Market Risk Adjusted Performance of 2.74, downside deviation of 4.83, and Risk Adjusted Performance of 0.1139. Gain Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Gain Therapeutics Price Movement Analysis

Gain Therapeutics Insider Trading Activities

Gain Therapeutics Outstanding Bonds

Gain Therapeutics Predictive Daily Indicators

Gain Therapeutics Corporate Filings

Gain Therapeutics Forecast Models

Gain Therapeutics' time-series forecasting models are one of many Gain Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Gain Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Gain Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Gain shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Gain Therapeutics. By using and applying Gain Stock analysis, traders can create a robust methodology for identifying Gain entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Gain analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Gain analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Gain Therapeutics stock analysis indicators help investors evaluate how Gain Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Gain Therapeutics shares will generate the highest return on investment. By understating and applying Gain Therapeutics stock analysis, traders can identify Gain Therapeutics position entry and exit signals to maximize returns.

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.